6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. J of Skin. 2023;7(6):s232. doi:10.25251/skin.7.supp.232